Equities

NLS Pharmaceutics AG

NLSP:NAQ

NLS Pharmaceutics AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.43
  • Today's Change0.065 / 1.93%
  • Shares traded64.50k
  • 1 Year change-79.09%
  • Beta-0.5281
Data delayed at least 15 minutes, as of Nov 22 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.

  • Revenue in USD (TTM)0.00
  • Net income in USD-6.60m
  • Incorporated2015
  • Employees3.00
  • Location
    NLS Pharmaceutics AGThe Circle 6ZUERICH 8058SwitzerlandCHE
  • Phone+41 445122150
  • Fax+41 445122151
  • Websitehttps://nlspharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NLSP:NAQ since
announced
Transaction
value
Kadimastem LtdAnnounced04 Nov 202404 Nov 2024Announced-4.72%--
Data delayed at least 15 minutes, as of Nov 22 2024 20:59 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Xenetic Biosciences Inc2.52m-4.08m6.19m4.00--0.8796--2.45-2.65-2.651.644.560.2523----630,855.00-40.76-48.91-45.48-52.82-----161.58-682.42----0.00--48.80--36.90------
Burzynski Research Institute Inc0.00-1.54m6.44m2.00---------0.0117-0.01170.00-0.00070.00-------89,888.89-15,304.89-------------------------45.74------
CNS Pharmaceuticals Inc0.00-17.06m6.44m3.00--1.30-----80.15-80.150.000.10020.00----0.00-350.34-132.47-2,116.75-185.75------------0.0092-------23.42------
Adial Pharmaceuticals Inc0.00-13.03m6.53m4.00--1.11-----4.49-4.500.000.91850.00----0.00-272.04-182.35-316.95-235.45-----------16.220.00------35.14------
Transcode Therapeutics Inc0.00-14.93m6.56m10.00--3.97-----8.49-8.490.000.09570.00----0.00-210.77-133.14-475.23-181.26-----------40.020.00-------5.59------
Brainstorm Cell Therapeutics Inc0.00-14.23m6.59m29.00---------3.46-3.460.00-1.140.00----0.00-369.22-117.19---231.65-----------35.87--------29.18---45.34--
NLS Pharmaceutics AG0.00-6.60m6.66m3.00---------6.72-6.720.00-9.400.00----0.00-380.82-272.62---------------27.20--------26.21------
National Graphite Corp0.00-1.97m6.79m0.00---------0.0221-0.02210.00-0.01930.00-------11,014.44-212.13---6,295.18---------------------1,432.70------
Edesa Biotech Inc0.00-6.93m6.85m16.00--2.39-----2.21-2.210.000.88290.00----0.00-94.60---128.81--------------0.00------52.28------
Cannabis Bioscience Internatnl Hlgs Inc354.91k-545.87k6.86m2.00------19.33-0.00005-0.000050.00003-0.00018.98--15.71177,455.00-1,381.60------87.28---153.81-----2.16-----21.46--36.92------
Virpax Pharmaceuticals Inc0.00-13.24m6.91m7.00---------8.82-8.820.00-0.41980.00----0.00-198.45-87.52-594.46-116.56-----------128.86--------29.84------
Syros Pharmaceuticals Inc386.00k-97.82m6.98m68.00------18.07-3.03-3.030.0105-0.41450.0033----5,676.47-84.04-54.44-111.15-64.32-----25,340.67-772.82---179.011.37---33.2337.12-73.87---27.78--
Biora Therapeutics Inc892.00k-35.57m7.07m58.00------7.93-12.92-11.780.2163-28.990.0363--1.0615,379.31-144.59-122.84---369.01-----3,988.12-415.10---------98.69-87.44-154.63---53.68--
Plus Therapeutics Inc (USA)5.73m-12.89m7.08m20.00------1.24-2.42-2.420.988-0.87750.5653----286,250.00-127.22-59.18---133.04-----225.07-470.45---4.31----2,093.30-5.8934.32--3.77--
ABVC Biopharma Inc509.80k-8.24m7.14m16.00--0.8363--14.00-0.9744-0.97440.05080.65760.0328--1.6031,862.50-56.14-103.38-88.09-231.5472.5476.25-1,710.03-2,019.89---2.620.1856---84.2885.3935.97------
Data as of Nov 22 2024. Currency figures normalised to NLS Pharmaceutics AG's reporting currency: US Dollar USD

Institutional shareholders

6.10%Per cent of shares held by top holders
HolderShares% Held
BVF Partners LPas of 30 Sep 2024143.68k5.81%
UBS Securities LLCas of 30 Sep 20244.72k0.19%
Quorus Verm�gensverwaltung AGas of 25 Sep 20242.50k0.10%
Armistice Capital LLCas of 30 Sep 20240.000.00%
Geode Capital Management LLCas of 30 Sep 20240.000.00%
BofA Securities, Inc.as of 30 Sep 20240.000.00%
Jane Street Capital LLCas of 30 Sep 20240.000.00%
HRT Financial LP (US)as of 30 Sep 20240.000.00%
Citadel Securities LLCas of 30 Sep 20240.000.00%
Renaissance Technologies LLCas of 30 Sep 20240.000.00%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.